Study on the Clinical Value of Wuqiyu® Acellular Matrix for Promoting Full-Thickness Repair of Uterine Incision Following Modified Double Flap Surgery in Patients with Adenomyosis

INTERVENTION: Control:Modified Double‐Flap Lesion Resection;group A:Combined application of Wuqiyu? Acellular Matri Xand modified double‐flap lesion resection; CONDITION: Adenomyosis PRIMARY OUTCOME: baseline characteristics, residual myometrial thickness, uterine volume, incidence of intrauterine adhesions, and serum CA125 levels;Proportion of patients with residual myometrial thickness (RMT) >= 10mm at 6 months after surgery; SECONDARY OUTCOME: Improvement of menstrual pain and chronic pelvic pain at 3 months and 6 months after surgery; INCLUSION CRITERIA: 1.Female patients aged >= 18 years; 2.Suffering from severe dysmenorrhea and/or menorrhagia; 3.Patients unsuitable for pharmacotherapy (including combined oral contraceptives, dienogest, gonadotropin‐releasing hormone agonist (GnRH‐a), or levonorgestrel intrauterine system) or with ineffective drug treatment; 4.Having a desire for uterus preservation or fertility preservation; 5.Preoperative diagnosis of diffuse adenomyosis of the anterior/posterior uterine wall with diffuse thickening of the myometrium confirmed by transvaginal ultrasound and/or MRI; 6.Voluntarily signing the informed consent form and being able to complete the full follow‐up;